Florida International University
Edit Your Profile
FIU Discovery
Toggle navigation
Browse
Home
People
Organizations
Scholarly & Creative Works
Research Facilities
Support
Edit Your Profile
GYNECOLOGIC ONCOLOGY
Journal
Overview
Research
Identifiers
Other
View All
Overview
publication venue for
Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a
BRCA1
or
BRCA2
mutation
. 152:145-150.
2019
Age-specific ovarian cancer risks among women with a
BRCA1
or
BRCA2
mutation
. 150:85-91.
2018
Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study
. 147:257-261.
2017
Risk of breast cancer after a diagnosis of ovarian cancer in
BRCA
mutation carriers: Is preventive mastectomy warranted?
. 145:346-351.
2017
The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma
. 143:258-263.
2016
Early-stage clear cell ovarian carcinoma and the effect of adjuvant radiation on survival
. 141:79.
2016
A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer
. 140:36-41.
2016
Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors
. 140:138-144.
2016
Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status
. 140:42-47.
2016
A model for estimating ovarian cancer risk: Application for preventive oophorectomy
. 139:242-247.
2015
The sooner the better: Genetic testing following ovarian cancer diagnosis
. 137:423-429.
2015
The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer
. 134:462-467.
2014
Incidence of port site hernias in robotic and laparoscopy assisted procedures in gynecologic oncology
. 133:196.
2014
Is pharmacologic prophylaxis indicated for prevention of thromboembolic disease after robotic and laparoscopic hysterectomy in a gynecologic oncology practice? Analysis of morbidity and cost in 1335 cases
. 133:150.
2014
Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients
. 131:667-673.
2013
Keeping it simple: Genetics referrals for all invasive serous ovarian cancers
. 130:329-333.
2013
Nonascites-forming advanced-stage serous ovarian cancer is related to a superior epithelial antigen presentation and enhanced infiltrating T-cell response
. 130:e132.
2013
The incidence of endometrial cancer in women with
BRCA1
and
BRCA2
mutations: An international prospective cohort study
. 130:127-131.
2013
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations
. 130:e42.
2013
Vaginal cuff complications decreased in total robotic vs. laparoscopic hysterectomy in cancer and noncancer patients: Bidirectional barbed vs. conventional suture
. 130:e160.
2013
Low-grade and high-grade serous Mullerian carcinoma: Review and analysis of publicly available gene expression profiles
. 128:488-492.
2013
Height, weight, BMI and ovarian cancer survival
. 127:83-87.
2012
Stage at diagnosis and ovarian cancer survival: Evidence from the International Cancer Benchmarking Partnership
. 127:75-82.
2012
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
. 121:353-357.
2011
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation
. 121:163-168.
2011
Multimodal therapy in the treatment of vaginal adenocarcinoma arising from endocervicosis
. 120:158-159.
2011
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
. 119:451-456.
2010
Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy
. 119:22-25.
2010
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube
. 118:299-302.
2010
Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers
. 118:295-298.
2010
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation
. 118:155-159.
2010
Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary
. 117:9-17.
2010
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York Cancer Consortium Study
. 116:442-446.
2010
Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: Is it time to change the gold standard?
. 116:28-32.
2010
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers
. 115:135-137.
2009
A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer
. 113:195-199.
2009
Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma
. 112:450-454.
2009
Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study
. 112:68-72.
2009
Radical vaginal trachelectomy vs. radical hysterectomy for small early stage cervical cancer: A matched case-control study
. 110:168-171.
2008
Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1
. 109:384-387.
2008
Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening - A case report
. 107:136-139.
2007
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III
. 106:453-460.
2007
Intraperitoneal chemotherapy for patients with advanced ovarian cancer: A review of the evidence and standards for the delivery of care
. 105:747-756.
2007
The risk of endometrial cancer in women with
BRCA1
and
BRCA2
mutations.: A prospective study
. 104:7-10.
2007
Uterine sarcoma occurring in a premenopausal patient after uterine artery embolization: A case report and review of the literature
. 104:260-263.
2007
Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study
. 100:324-329.
2006
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers
. 100:58-64.
2006
Hormone replacement therapy and the risk of ovarian cancer in
BRCA1
and
BRCA2
mutation carriers
. 100:83-88.
2006
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium
. 100:160-165.
2006
Sigmoid impaction secondary to urinary stones: Case report and review of literature
. 97:234-237.
2005
The use of transrectal ultrasound to biopsy pelvic masses in women
. 95:552-556.
2004
Conversion of an incontinent urinary conduit to a continent urinary reservoir (Miami Pouch)
. 94:814-817.
2004
A comparison of laparascopic-assisted radical vaginal hysterectomy and radical abdominal hysterectomy in the treatment of cervical cancer
. 93:588-593.
2004
Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study
. 93:144-148.
2004
Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies
. 89:420-423.
2003
Peritoneal lavage cytology: An assessment of its value during prophylactic oophorectomy
. 85:397-403.
2002
Expression of glucose transporter-1 in cervical cancer and its precursors
. 86:138-143.
2002
How important is removal of the parametrium at surgery for carcinoma of the cervix?
. 84:145-149.
2002
Psychological adjustment to familial-genetic risk assessment for ovarian cancer: Predictors of nonadherence to surveillance recommendations
. 84:72-80.
2002
Radical vaginal trachelectomy after supracervical hysterectomy
. 85:545-547.
2002
Vaginal reconstruction at the time of pelvic exenteration: A surgical and psychosexual analysis of techniques
. 87:39-45.
2002
Allelotype of papillary serous peritoneal carcinomas
. 82:69-76.
2001
Changes in the demographics and perioperative care of stage IA
2
/IB
1
cervical cancer over the past 16 years
. 81:133-137.
2001
A genetic epidemiological study of carcinoma of the fallopian tube
. 80:341-345.
2001
Pattern of lymph node metastases in clinically unilateral stage invasive epithelial ovarian carcinomas
. 80:56-61.
2001
Information needs and decisional preferences among women with ovarian cancer
. 77:357-361.
2000
A longitudinal study of psychological adjustment to familial genetic risk assessment for ovarian cancer
. 74:331-337.
1999
Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas
. 74:202-207.
1999
A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer
. 72:292-297.
1999
Primary uterine angiosarcoma
. 75:272-276.
1999
Psychological impact of screening for familial ovarian cancer: Reactions to initial assessment
. 65:197-205.
1997
Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer
. 64:425-430.
1997
LETTERS TO THE EDITOR
. 62:427-428.
1996
Patients' preferences for therapy in advanced epithelial ovarian cancer: Development, testing, and application of a bedside decision instrument
. 62:329-335.
1996
Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix
. 61:416-422.
1996
In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration
. 61:175-179.
1996
DOES AGGRESSIVE THERAPY IMPROVE SURVIVAL IN SUBOPTIMAL STAGE-IIIC-IV OVARIAN-CANCER - A CANADIAN-AMERICAN COMPARATIVE-STUDY
. 59:194-199.
1995
METAANALYSIS COMPARING CISPLATIN TOTAL-DOSE INTENSITY AND SURVIVAL
. 59:93-101.
1995
A PROSPECTIVE RANDOMIZED COMPARISON OF AN ATTACHED SILVER-IMPREGNATED CUFF TO PREVENT CENTRAL VENOUS CATHETER-ASSOCIATED INFECTION
. 58:92-100.
1995
A PHASE-I TRIAL OF CYCLOSPHOSPHAMIDE AND CARBOPLATINUM COMBINED WITH INTERLEUKIN-3 IN WOMEN WITH ADVANCED-STAGE OVARIAN-CANCER
. 56:387-394.
1995
LIPID-SOLUBLE ANTIOXIDANTS - BETA-CAROTENE AND ALPHA-TOCOPHEROL LEVELS IN BREAST AND GYNECOLOGIC CANCERS
. 55:72-77.
1994
HIGH-DOSE METHOTREXATE FOR GESTATIONAL TROPHOBLASTIC DISEASE
. 54:282-287.
1994
DIFFERENCES IN THE MORBIDITY OF RADICAL HYSTERECTOMY BETWEEN GYNECOLOGICAL ONCOLOGISTS
. 51:39-45.
1993
PLATINUM CHEMOTHERAPY DURING PREGNANCY FOR SEROUS CYSTADENOCARCINOMA OF THE OVARY
. 49:92-94.
1993
ENDOMETRIAL ADENOCARCINOMA - GENETIC-ANALYSIS SUGGESTING HERITABLE SITE-SPECIFIC UTERINE-CANCER
. 47:167-171.
1992
LYMPH-NODE SAMPLING IN PATIENTS WITH EPITHELIAL OVARIAN-CARCINOMA
. 47:143-145.
1992
Endometrial adenocarcinoma: Genetic analysis indicating heritable site-specific uterine cancer
. 45:81.
1992
Lymph node sampling in patients with epithelial ovarian carcinoma
. 45:77.
1992
Pilot clinical trial of cisplatin (CDDP), radiation therapy (RT), and WR2721 in carcinoma of the uterine cervix (CC)
. 45:85.
1992
Surgical management of patients with endometrial cancer and cervical involvement
. 45:97-98.
1992
CA-125 - A POTENTIAL PROGNOSTIC INDICATOR IN PATIENTS WITH CERVICAL-CANCER
. 40:222-224.
1991
CA125-a potential prognostic indicator in patients with cervical carcinoma?
. 40:189.
1991
The response of the small cell cancer of the ovary with hypercalcemia to sequencing chemotherapy
. 40:178.
1991
The role of anemia in predicting treatment outcome in locally advanced cervical carcinoma
. 40:186.
1991
A SUCCESSFUL TERM PREGNANCY FOLLOWING THE SYSTEMIC AND INTRAPERITONEAL ADMINISTRATION OF CISPLATIN CHEMOTHERAPY
. 39:378-380.
1990
HETEROGENEITY IN HORMONE RECEPTOR STATUS IN PRIMARY AND METASTATIC ENDOMETRIAL CANCER
. 38:437-441.
1990
OVARIAN CONSERVATION IN PLACENTAL SITE TROPHOBLASTIC TUMOR
. 37:239-243.
1990
Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells
. 36:291.
1990
CONCOMITANT CISPLATIN AND RADIOTHERAPY IN LOCALLY ADVANCED CERVICAL-CARCINOMA
. 34:395-401.
1989
CONCURRENT RADIATION AND CHEMOTHERAPY IN VULVAR CARCINOMA
. 34:263-267.
1989
ARTERIAL EMBOLIZATION IN THE MANAGEMENT OF ABDOMINAL AND RETROPERITONEAL HEMORRHAGE
. 34:131-135.
1989
COLPOSCOPIC AND CYTOLOGIC DETECTION OF CHRONIC LYMPHOCYTIC-LEUKEMIA
. 34:106-108.
1989
IMMUNE-COMPLEXES IN OVARIAN-CARCINOMA
. 32:350-353.
1989
Clinical options: Small cell CA ovary
. 32:127.
1989
Concomitant cisplatin (DDP) and radiotherapy (RT) in locally advanced cervical carcinoma (CX CA)
. 32:126-127.
1989
Concurrent radiation and chemotherapy in vulvar carcinoma
. 32:122-123.
1989
Incidence of clostridium difficile (CD) infection in patients (pis.) with diarrhea (D) on a gynecologic oncology service
. 32:120.
1989
Ovarian cancer grows intraperitoneally due to growth factors present in ascitic fluid: Development of animal model systems and methods to block ascitic fluid growth factor activity
. 32:104.
1989
The Kock pouch in previously irradiated gynecological patients
. 32:127-128.
1989
CONTINUOUS INFUSION FLUOROPYRIMIDINES AS SALVAGE THERAPY FOR PATIENTS WITH ADVANCED OVARIAN-CARCINOMA
. 29:348-355.
1988
CATHETER COMPLICATIONS ASSOCIATED WITH INTRAPERITONEAL CHEMOTHERAPY
. 24:41-50.
1986
ELEVATION OF SERUM CA 125 PRIOR TO DIAGNOSIS OF AN EPITHELIAL OVARIAN-CARCINOMA
. 22:115-120.
1985
CA-125 is a useful predictor of disease status in uterine carcinosarcoma
2018
Education Forum I: Immunotherapy 2018: Updates and Toxicities Saturday, March 24, 2018
2018
Immune checkpoint blockade and a neoepitope vaccine in a metastatic ovarian cancer model
2018
Is VTE chemoprophylaxis beneficial after robotic hysterectomy with staging for uterine cancer? An analysis of prevalence, prophylaxis and Caprini risk assessment model among 332 patients
2017
Omental disease has a significant impact on overall survival in patients with uterine carcinosarcoma
2017
Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival
2017
Utility of indocyanine green (ICG) dye with Firefly fluorescence imaging alone or combined with methylene blue dye for detection of sentinel lymph nodes in endometrial and cervical cancer, and discriminative ability for detecting metastases
2017
Radical abdominal and robotic hysterectomy: Perioperative and oncologic outcome of 175 cases
2015
Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: A study of morbidity and survival
2004
The gastrointestinal complications of the Miami Pouch: A review of 77 cases
2004
Surgery "ain't" going to cut it. Are we ready?
2002
Re: Meta-analysis comparing cisplatin total dose intensity and survival: A critical reappraisal
1996
Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan
1998
Untitled - Reply
1996
CECAL CANCER IN A TEENAGER PRESENTING WITH A PELVIC MASS - A CASE-REPORT AND REVIEW OF THE LITERATURE
1994
ANALYSIS FOR STEROID-PRODUCTION OF A SERTOLI-LEYDIG CELL TUMOR
1994
Why have ovarian cancer mortality rates declined? Part I. Incidence
2015
Why have ovarian cancer mortality rates declined? Part II. Case-fatality
2015
Why have ovarian cancer mortality rates declined? Part III. Prospects for the future
2015
Endometrial cancer: A review and current management strategies: Part I
2014
Endometrial cancer: A review and current management strategies: Part II
2014
The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer
2010
Who should operate on patients with ovarian cancer? An evidence-based review
2005
Systematic review of management options for women with a hereditary predisposition to ovarian cancer
2004
ADJUVANT THERAPY FOR NEUROENDOCRINE SMALL-CELL CARCINOMA OF THE CERVIX - REVIEW OF THE LITERATURE
1991
Fanconi anemia repair pathway as a predictor of anti-tumor activity of pembrolizumab: interim analysis of open-label, single-arm phase II trial
2021
Granulosa cell tumors: A SEER data review of prognostic parameters in 1815 patients
2017
Neoadjuvant chemotherapy and cycle number: A national multicentre study
2017
The sooner the better: Genetic testing following ovarian cancer diagnosis (vol 137, pg 423, 2015)
2017
Surgical factors do not impact survival in high-grade serous ovarian carcinoma patients treated with neoadjuvant chemotherapy
2015
Endometrial cancer: A review and current management strategies: Part I (vol 134, pg 385, 2014)
2014
Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers?
2014
Multi-center gene expression analysis of Mullerian low-grade and high-grade serous carcinoma highlights genes potentially involved in chemotherapy resistance
2012
Implementation of surgical treatment for early-stage cervical cancer by Kenyan gynecologists in western Kenya
2011
Saul B. Gusberg, MD. In memoriam
2005
TO P-32 OR NOT TO P-32, THAT IS THE QUESTION
1993
ASCITIC FLUID FROM OVARIAN-CANCER PATIENTS CONTAINS A UNIQUE GROWTH-FACTOR WHICH STIMULATES OVARIAN-CANCER CELLS - CHARACTERIZATION, PURIFICATION, AND MECHANISM OF ACTION
1988
Research
category
OBSTETRICS & GYNECOLOGY
Category
ONCOLOGY
Category
Identifiers
International Standard Serial Number (ISSN)
0090-8258
Electronic International Standard Serial Number (EISSN)
1095-6859
Other
journal abbreviation
GYNECOL ONCOL
